The bill amends the Federal Food, Drug, and Cosmetic Act to make shrimp an explicitly regulated import category: FDA must seek agreements with foreign governments that have registered facilities producing shrimp for the U.S., and may refuse admission of shrimp from countries that do not enter such agreements or whose food inspection systems are not equivalent to FDA’s standards for shrimp. Equivalence is framed around demonstrable staffing for uniform enforcement and enforcement of laws governing how shrimp are raised and transported to processing facilities.
Practically, the bill creates a one-year compliance window after enactment (arrangements must be sought within 180 days; refusals may begin one year after enactment), adds a new “adulteration” basis for refusing shrimp at the border, and requires annual reporting to congressional committees on implementation. The change shifts clearance questions from product-level testing toward country-level inspection-system evaluation, with direct consequences for exporters, importers, and FDA resources.
At a Glance
What It Does
The bill adds a new subsection to section 807 of the FD&C Act requiring FDA to seek agreements with foreign governments that host registered shrimp facilities and sets a rule that shrimp from countries without such agreements—or without inspection systems FDA finds equivalent—shall be refused entry. It also amends the adulteration provision to make noncompliant imported shrimp subject to refusal and mandates annual reporting to Congress.
Who It Affects
Foreign governments and their national or subnational inspection agencies that oversee shrimp production and processing; foreign facilities registered under section 415 that manufacture, process, pack, or hold shrimp for the U.S.; U.S. importers, distributors, and retailers of shrimp; FDA and federal port inspection authorities who will implement equivalence assessments and import refusals.
Why It Matters
The bill replaces or supplements product-level controls with a country-level equivalence regime for shrimp, creating a chokepoint that can immediately stop imports from noncompliant countries. That design can quickly reduce public-health risk but also concentrates enforcement and trade impact at the national-government level, raising implementation and trade-law trade-offs.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill narrowly targets shrimp by adding a new subsection to the FDA’s foreign facility framework. It requires the Secretary of Health and Human Services (acting through FDA) to initiate arrangements or agreements with every foreign government that has one or more foreign facilities registered under section 415 and that manufacture, process, pack, or hold shrimp for consumption in the United States.
The bill gives FDA 180 days after enactment to begin negotiating those arrangements.
If a foreign government does not enter into an arrangement with FDA, or if FDA determines that the government’s food inspection system is not equivalent for shrimp, the bill declares that shrimp manufactured, processed, packed, or held in that country shall be refused admission into the United States beginning one year after enactment. Equivalence is defined functionally: the foreign system must demonstrate staffing sufficient to ensure uniform enforcement and must enforce laws and regulations that address conditions where shrimp are raised and transported to processing establishments.To support equivalence findings, foreign governments must provide copies of laws, regulations, and other relevant information.
The bill also amends the FD&C Act’s adulteration section to include shrimp that are imported from countries that fail to comply with the new section 807(c), giving FDA a statutory basis to treat such imports as adulterated and refuse them at the border. Finally, the statute requires FDA to report to the Senate Committee on Health, Education, Labor, and Pensions and the House Committee on Energy and Commerce within one year of enactment and annually thereafter on how the new rules are being implemented.
The Five Things You Need to Know
FDA must seek arrangements with each foreign government that hosts one or more section 415–registered facilities producing shrimp for the U.S.
and it must begin that outreach within 180 days of enactment.
Starting one year after enactment, shrimp will be refused admission if the exporting country either has not entered an FDA arrangement or its food inspection system fails to meet the bill’s equivalence criteria.
The bill’s equivalence standard is operational: a country must demonstrate staffing that ensures uniform enforcement and enforce laws covering how shrimp are raised and transported to processing establishments.
To demonstrate equivalence, a foreign government must provide FDA copies of all relevant laws, regulations, and other information about its inspection system; the bill does not prescribe on-site inspection frequency or an appeals process.
The bill amends the FD&C Act’s adulteration provision so that imported shrimp from noncompliant countries are explicitly ‘‘adulterated,’’ and it requires FDA to submit an initial report within one year and annual reports thereafter to specified congressional committees.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Mandate to seek arrangements with shrimp-exporting governments
This paragraph requires FDA to seek to enter into arrangements or agreements with the foreign government of each country that has one or more facilities registered under section 415 that manufacture, process, pack, or hold shrimp for the U.S. The practical implication is that FDA must identify all countries with registered shrimp facilities and open formal government-level negotiations; the bill gives FDA a 180-day deadline to start that process, which compresses workload for international outreach and documentation.
Refusal of admission of shrimp from noncompliant countries
This provision creates a country-level bar on entry: beginning one year after enactment, shrimp from countries that either fail to reach an arrangement with FDA or whose inspection systems do not meet the bill’s criteria shall be refused admission. Operationally, this shifts a key enforcement decision to customs and FDA import reviewers and turns national equivalence into an admission/denial trigger rather than a discretionary enforcement tool.
Equivalence criteria focused on staffing and enforcement of raising/transport rules
The bill sets two concrete elements the Secretary must look for when evaluating a country’s food inspection system: (A) staffing sufficient to ensure uniform enforcement of applicable laws and regulations, and (B) enforcement of laws addressing the conditions where shrimp are raised and transported to processing establishments. The criteria are narrowly described, leaving FDA authority to interpret what staffing levels or enforcement practices suffice but tying equivalence to system-level capacity rather than specific testing protocols.
Demonstration materials required from foreign governments
To prove equivalence, foreign governments must provide copies of all laws, regulations, and other information about their food inspection systems. The bill does not require a particular format or timeline for submission beyond the general deadlines for FDA outreach, nor does it require FDA to inspect every facility; it centers the evaluation on documentary evidence and, implicitly, subsequent FDA judgment on whether those materials demonstrate equivalence.
Adulteration basis for refusal and annual implementation reports
The bill adds a subsection to the adulteration provision to specify that shrimp imported from countries whose governments or inspection systems do not comply with section 807(c) are ‘‘adulterated’’ for purposes of enforcement. That statutory labeling supports denial at the border and other enforcement actions. Separately, FDA must report to the Senate HELP Committee and House Energy and Commerce Committee within one year and annually thereafter describing implementation—creating a recurring congressional oversight channel tied directly to enforcement outcomes.
This bill is one of many.
Codify tracks hundreds of bills on Trade across all five countries.
Explore Trade in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- U.S. consumers and public-health agencies — by creating a clearer statutory path to block shrimp imports from countries whose inspection systems FDA deems inadequate, potentially reducing exposure to contaminants, pathogens, or unsafe production practices.
- Domestic shrimp producers and processors — because import refusals from noncompliant countries can reduce competitive pressures from foreign suppliers operating under weaker oversight, improving market conditions for domestic product.
- Retailers and foodservice operators that prioritize supply-chain safety — they gain a statutory tool that can reduce variability in supplier practices and make supplier due diligence more straightforward when sourcing from countries with FDA agreements.
Who Bears the Cost
- Foreign shrimp-exporting governments and producers — they must document and possibly reform their inspection regimes, allocate staffing, and produce legal/regulatory materials to demonstrate equivalence, or face a loss of U.S. market access.
- U.S. importers, distributors, and some retailers — they face supply disruption risk, reduced supplier options, and potential cost increases if key supply countries are deemed noncompliant and shipments are refused.
- FDA and federal inspection resources — the agency must negotiate agreements, assess equivalence claims, review documentary materials, and coordinate refusals and reporting, creating administrative and resource demands that the bill does not fund explicitly.
Key Issues
The Core Tension
The bill pits a desire for robust, country-level protection of the U.S. food supply against the practical and diplomatic costs of enforcing equivalence: stricter, faster action protects consumers but risks trade disruption and strains FDA’s capacity, while a more measured approach reduces market shocks but may leave unsafe imports entering the supply chain.
The bill sets a country-level equivalence test but leaves critical procedural and evidentiary questions unresolved. It requires foreign governments to provide laws and regulations and commits FDA to judge equivalence, but it does not specify how FDA will evaluate staffing levels, the metrics for ‘‘uniform enforcement,’’ or the threshold for acceptable enforcement of on-farm and transport conditions — all concepts that are operationally complex and vary by national administrative structure.
That ambiguity creates room for inconsistent application and for disputes over whether FDA’s determinations reflect substantive safety gaps or differing regulatory approaches.
A second tension concerns trade and implementation capacity. Turning national inspection systems into gatekeepers can quickly stop imports from entire countries, producing abrupt supply shocks and price effects in the U.S. market.
It also creates potential trade-friction points: affected countries may challenge FDA conclusions under trade agreements or seek remediation through bilateral channels. Finally, the bill places a nontrivial administrative load on FDA—negotiating arrangements, reviewing legal materials, adjudicating equivalence, conducting enforcement at ports, and producing annual reports—without specifying resource allocations, timelines for deeper verification (such as on-site audits), or an appeal and remediation mechanism for countries or importers.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.